Adeona Pharmaceuticals, Inc. (AEN), a development-stage, specialty pharmaceutical company, has dedicated its efforts to developing proprietary, late-stage drug candidates designed to treat autoimmune and central nervous system (CNS) diseases. The company’s strategy is to exclusively in-license proprietary, clinical-stage drug candidates that have proven clinical efficacy for the treatment medical diseases that are as of yet unattended to. For further information, visit the Company’s web site at www.adeonapharma.com.
- 17 years ago
QualityStocks
Adeona Pharmaceuticals, Inc. AEN)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – MAX Power Mining (CSE: MAXX) (OTC: MAXXF) (FRANKFURT: 89N) Expands Natural Hydrogen Exploration with New Bracken Target in Saskatchewan
MAX Power Mining (CSE: MAXX) (OTC: MAXXF) (FRANKFURT: 89N) announced the identification of “Bracken” as…
-
QualityStocksNewsBreaks – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Featured in NetworkNewsAudio on Advancing 3D AI-Imaging Technologies
Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) is spotlighted in a NetworkNewsAudio release titled “Investors…
-
QualityStocksNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Founder Gareth Sheridan Returns as CEO to Lead Final Development Phase of AVERSA Fentanyl
Nutriband (NASDAQ: NTRB) today announced that company founder Gareth Sheridan has resumed his role as…